2022 World Conference on Lung Cancer (ePosters)-EP05.01-016. Radiation Recall Pneumonitis (RRP) Induced by Immune Checkpoint Inhibitors (ICIs) after Thoracic Radiotherapy for Lung Cancer

EP05.01-016. Radiation Recall Pneumonitis (RRP) Induced by Immune Checkpoint Inhibitors (ICIs) after Thoracic Radiotherapy for Lung Cancer

Back to course

Pdf Summary

This study examined the incidence, characteristics, and risk factors of Radiation Recall Pneumonitis (RRP) induced by Immune Checkpoint Inhibitors (ICIs) after thoracic radiotherapy in Chinese lung cancer patients. A total of 196 patients with a history of lung irradiation and who received ICIs were included in the study. RRP was defined as inflammatory reactions at previously irradiated areas after ICIs administration and 6 months after radiotherapy. The study found that RRP occurred in 14 patients, with a median interval of 271 days between the end of radiotherapy and RRP, and a median interval of 147 days between the initiation of ICIs and RRP. Glucocorticoid treatment was effective in treating grade 2 RRP, and all patients recovered from RRP. Patients with a history of chronic pulmonary diseases, higher mean lung dose, higher volume more than 5Gy, and higher volume more than 20Gy had a significantly higher incidence of RRP. Dosimetric parameters, including mean lung dose (MLD), volume more than 5Gy (V5), and volume more than 20Gy (V20), were identified as predictive factors for the development of RRP. Smoking history, sex, age, lower lobe irradiation, types of ICI therapy, prior radiation pneumonitis, and the interval between radiotherapy and ICI were not associated with the development of RRP. The study concludes that RRP is manageable in this population of lung cancer patients receiving ICIs after thoracic radiotherapy, and dosimetric parameters can help predict the risk of RRP.

Asset Subtitle

Xiaotong Lu

Meta Tag

Speaker Xiaotong Lu

Topic Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

Keywords

Radiation Recall Pneumonitis

Immune Checkpoint Inhibitors

Thoracic radiotherapy

Chinese lung cancer patients

Inflammatory reactions

Glucocorticoid treatment

Chronic pulmonary diseases

Mean lung dose

Volume more than 5Gy

Volume more than 20Gy